A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab (pembro), lenvatinib, and chemotherapy in patients (pts) with metastatic non-small cell lung cancer (NSCLC) harbouring a targetable mutation who experienced disease progression on standard tyrosine kinase inhibitors (TKIs)
198 Background: Pts with metastatic NSCLC harbouring a targetable mutation who progressed on standard TKIs often receive chemotherapy as the next line of treatment. We report efficacy and safety of a novel combination of pembro, lenvatinib and chemotherapy for these pts. Methods: This was a phase 2,...
Saved in:
Published in | Journal of clinical oncology Vol. 42; no. 23_suppl; p. 198 |
---|---|
Main Authors | , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
10.08.2024
|
Online Access | Get full text |
Cover
Loading…
Abstract | 198 Background: Pts with metastatic NSCLC harbouring a targetable mutation who progressed on standard TKIs often receive chemotherapy as the next line of treatment. We report efficacy and safety of a novel combination of pembro, lenvatinib and chemotherapy for these pts. Methods: This was a phase 2, open-label, single-centre, single-arm study enrolling pts with metastatic NSCLC with sensitizing EGFR, ALK or ROS1 mutation who progressed on standard TKIs. Eligible pts had measurable disease, no untreated brain metastasis and ECOG PS ≤1. Pts received pembro 200 mg, pemetrexed 500 mg/m 2 and carboplatin AUC 5 every 3 weeks for 4 cycles plus lenvatinib 8 mg QD. The maintenance regimen without carboplatin was continued as tolerated for up to 2 years. The primary endpoint was objective response rate (ORR) by independent radiology review (IRR) as per RECIST 1.1. The secondary endpoints were PFS, overall survival (OS) and safety. Results: At the data cutoff date (2 nd February 2024), 24 pts were screened and 19 were enrolled: median age 64 years (range 29–77); 10 (53%) female. Four pts were excluded at screening due to untreated brain metastasis. All enrolled pts were evaluated for safety while 15 pts were evaluable for response. All pts had adenocarcinoma with targetable mutation: EGFR mutation in 18 (95%) pts and ALK fusion in 1 (5%) pt. The median follow-up time was 11.3 months. Treatment was ongoing in 8 pts on the date of analysis, while 6 pts permanently discontinued due to disease progression and 1 pt permanently discontinued due to a treatment-related adverse event (TRAE). The ORR was 40% (6/15, 95% CI 19.8%–64.3%). All responses were partial responses. The median PFS was 11.9 months (range 3.5–20.3). The OS was not reached. TRAEs of any grade (Gr) occurred in 74% (14/19) of the pts. Most of the TRAEs were Gr 1–2, which occurred in 63% (12/19) of the pts. The most common TRAEs were hypothyroidism (31.6%), nausea (26.3%), neutropenia (26.3%), thrombocytopenia (26.3%), anorexia (21.1%), hypertension (15.8%), anaemia (10.5%), pruritus (10.5%) and rash (10.5%). G1 diarrhoea was reported in 1 pt (5.3%) and G1 adrenal insufficiency in 1 pt (5.3%). Gr 3 TRAEs were neutropenia in 2 pts, anaemia in 1 pt and thrombocytopenia in 1 pt. The only Gr 4 TRAE was thrombocytopenia. No treatment related death was observed. Conclusions: The combination of pembro, lenvatinib and chemotherapy demonstrated a favourable ORR and safety in treating metastatic NSCLC pts with a targetable mutation who progressed on standard TKIs. Clinical trial information: NCT04989322 . |
---|---|
AbstractList | 198 Background: Pts with metastatic NSCLC harbouring a targetable mutation who progressed on standard TKIs often receive chemotherapy as the next line of treatment. We report efficacy and safety of a novel combination of pembro, lenvatinib and chemotherapy for these pts. Methods: This was a phase 2, open-label, single-centre, single-arm study enrolling pts with metastatic NSCLC with sensitizing EGFR, ALK or ROS1 mutation who progressed on standard TKIs. Eligible pts had measurable disease, no untreated brain metastasis and ECOG PS ≤1. Pts received pembro 200 mg, pemetrexed 500 mg/m 2 and carboplatin AUC 5 every 3 weeks for 4 cycles plus lenvatinib 8 mg QD. The maintenance regimen without carboplatin was continued as tolerated for up to 2 years. The primary endpoint was objective response rate (ORR) by independent radiology review (IRR) as per RECIST 1.1. The secondary endpoints were PFS, overall survival (OS) and safety. Results: At the data cutoff date (2 nd February 2024), 24 pts were screened and 19 were enrolled: median age 64 years (range 29–77); 10 (53%) female. Four pts were excluded at screening due to untreated brain metastasis. All enrolled pts were evaluated for safety while 15 pts were evaluable for response. All pts had adenocarcinoma with targetable mutation: EGFR mutation in 18 (95%) pts and ALK fusion in 1 (5%) pt. The median follow-up time was 11.3 months. Treatment was ongoing in 8 pts on the date of analysis, while 6 pts permanently discontinued due to disease progression and 1 pt permanently discontinued due to a treatment-related adverse event (TRAE). The ORR was 40% (6/15, 95% CI 19.8%–64.3%). All responses were partial responses. The median PFS was 11.9 months (range 3.5–20.3). The OS was not reached. TRAEs of any grade (Gr) occurred in 74% (14/19) of the pts. Most of the TRAEs were Gr 1–2, which occurred in 63% (12/19) of the pts. The most common TRAEs were hypothyroidism (31.6%), nausea (26.3%), neutropenia (26.3%), thrombocytopenia (26.3%), anorexia (21.1%), hypertension (15.8%), anaemia (10.5%), pruritus (10.5%) and rash (10.5%). G1 diarrhoea was reported in 1 pt (5.3%) and G1 adrenal insufficiency in 1 pt (5.3%). Gr 3 TRAEs were neutropenia in 2 pts, anaemia in 1 pt and thrombocytopenia in 1 pt. The only Gr 4 TRAE was thrombocytopenia. No treatment related death was observed. Conclusions: The combination of pembro, lenvatinib and chemotherapy demonstrated a favourable ORR and safety in treating metastatic NSCLC pts with a targetable mutation who progressed on standard TKIs. Clinical trial information: NCT04989322 . |
Author | Lo, Jenny WY Tse, Chris Chun Long Wong, Jeffrey Sum Lung Ho, James CM Tang, Vikki Li, Hoi Lam Chan, Hoi Wai Hui, Rina Li, Yu-Chung Chiu, Joanne W Tsang, Wing Yan Josephine Kwok, Gin Wai Li, Cho Wing Yau, Thomas Leung, Roland Ching-Yu |
Author_xml | – sequence: 1 givenname: Hoi Wai surname: Chan fullname: Chan, Hoi Wai organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 2 givenname: Chris Chun Long surname: Tse fullname: Tse, Chris Chun Long organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 3 givenname: Yu-Chung surname: Li fullname: Li, Yu-Chung organization: Hong Kong United Oncology Centre, Hong Kong, Hong Kong – sequence: 4 givenname: Roland Ching-Yu surname: Leung fullname: Leung, Roland Ching-Yu organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 5 givenname: Jeffrey Sum Lung surname: Wong fullname: Wong, Jeffrey Sum Lung organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 6 givenname: Gin Wai surname: Kwok fullname: Kwok, Gin Wai organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 7 givenname: Hoi Lam surname: Li fullname: Li, Hoi Lam organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 8 givenname: Wing Yan Josephine surname: Tsang fullname: Tsang, Wing Yan Josephine organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 9 givenname: Cho Wing surname: Li fullname: Li, Cho Wing organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 10 givenname: Jenny WY surname: Lo fullname: Lo, Jenny WY organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 11 givenname: Vikki surname: Tang fullname: Tang, Vikki organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 12 givenname: Rina surname: Hui fullname: Hui, Rina organization: Centre of Cancer Medicine, School of Clinical Medicine, The University of Hong Kong, Hong Kong, Hong Kong – sequence: 13 givenname: Thomas surname: Yau fullname: Yau, Thomas organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 14 givenname: James CM surname: Ho fullname: Ho, James CM organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong – sequence: 15 givenname: Joanne W surname: Chiu fullname: Chiu, Joanne W organization: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong |
BookMark | eNqlkctu20AMRdUiAWKn-QcubcBSpJENO8vASJE-0C6aRXYDSqKtaeaFmZET5etLNekXdMMBhzzgvbjz7Mw6S1kGVVlUoiyvv-5_FqIU62ItClHLOHivi-pm9zGbVRuxzbfbzeYsm5XbWuTVrn68yOYx_i7Lar2rN7MP4hZ8j5FArMB5srnGhvQKorJHTTkGAzEN3Qh0Qj1g4m9IPUHrTKMs986CO4An0wSn1etgsIHFW7tcgSZ7miDVrABtB21PxjEf0I-gLHgekk2RkRSX8KxSD4YSxsSDFthrHg1qDS1x0QNfb9G2FGDx49f--34JPYbGDWHShZAwHJluNIEZ0pu6594BvXgKfKilDjoVaTLsgzsGivGvA8suWR-GDtIYHLsneGJ_vKdsrxqVXGCRD9--xOWn7PyAOtLV-3uZ7T7fPezv85bBGOggfVAGwyirUk4ZSc5IThnJtZD_MpKcUf0f6B8oXKlT |
ContentType | Journal Article |
DBID | AAYXX CITATION |
DOI | 10.1200/JCO.2024.42.23_suppl.198 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1527-7755 |
EndPage | 198 |
ExternalDocumentID | 10_1200_JCO_2024_42_23_suppl_198 |
GroupedDBID | --- .55 0R~ 18M 34G 39C 4.4 53G 5GY 5RE 8F7 AAQQT AARDX AAWTL AAYEP AAYXX ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS AWKKM BAWUL C45 CITATION CS3 DIK EBS EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 IPNFZ K-O KQ8 L7B LSO MJL N9A O9- OK1 OVD OWW P2P QTD R1G RHI RIG RLZ RUC SJN SV3 TEORI TR2 TWZ UDS VVN WH7 X7M YCJ YFH YQY |
ID | FETCH-crossref_primary_10_1200_JCO_2024_42_23_suppl_1983 |
ISSN | 0732-183X |
IngestDate | Fri Aug 23 04:24:33 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 23_suppl |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-crossref_primary_10_1200_JCO_2024_42_23_suppl_1983 |
ParticipantIDs | crossref_primary_10_1200_JCO_2024_42_23_suppl_198 |
PublicationCentury | 2000 |
PublicationDate | 2024-08-10 |
PublicationDateYYYYMMDD | 2024-08-10 |
PublicationDate_xml | – month: 08 year: 2024 text: 2024-08-10 day: 10 |
PublicationDecade | 2020 |
PublicationTitle | Journal of clinical oncology |
PublicationYear | 2024 |
SSID | ssj0014835 |
Score | 5.011889 |
Snippet | 198 Background: Pts with metastatic NSCLC harbouring a targetable mutation who progressed on standard TKIs often receive chemotherapy as the next line of... |
SourceID | crossref |
SourceType | Aggregation Database |
StartPage | 198 |
Title | A phase 2, open-label, single-arm study evaluating the combination of pembrolizumab (pembro), lenvatinib, and chemotherapy in patients (pts) with metastatic non-small cell lung cancer (NSCLC) harbouring a targetable mutation who experienced disease progression on standard tyrosine kinase inhibitors (TKIs) |
Volume | 42 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3db5NQFMCv20yML0anxu-cB13aAB29pYM-No1mOuem1tg9EWDUEgc0BWK6_8b_1HPuvXCZ0-iWNKSl4RZ6-HHOPfd8MPYycue0fHVquZ7tWc78tG8FbuhYsRcPUGHZjiscbocf9va_OO9mw9nG5s9W1FJVhr3o_I95JdeRKu5DuVKW7BUk2wyKO_A9yhe3KGHc_peMx8ZygVrI4PRHUR8sC2Uql93JBXAWW8EqlRVkm7LeKjsKTwfnxI29uIzTkPr3nFdpEJLVKXe84iMaDDUTeW6zJKyDPVHUqcrdEomDqjyrcOEuKTJjJD28aVwGlLOUREaWZ1aR0ko4LRYYZxVl-9I9txIdgT5P3k_osEWwIkeryJ00ZJy6yO5KKxUX-WORq74EsQheUEtMMtJMVhmhFZDGR1Ku0RAgW_o7Xm9BNVIWSZiIJkP4u9ODt0XtDblsozd5o3kWXVh_oKQMobXzxPgaJI3_Q7apFBUbcFtRS2RlGlDQk4icOKks-kbvjdXz9lNOUaaio_k366Rq-2O4Y4n6uK3HtjvgFj4oZ1LDKrXCXZzHyILEtd5xeIsvPvALauPa0iV92Z5bmSXq0yWNx2Uz78lRj06m5_BePVSvGaBdZPw35d-EZNJkkNPK5uTIp5F8h_v1SD6OtMlucnc0pKjZg496oc7xZA_b-qJVsByOtPu3c2pZgC1TbnqX3VHyhbEE6h7biLNtdutQRZlss51jWc99bcJUpycWJuzAsa70vr5_g49BAAjcBI2fCRo-EPCBhg8QGmjBB_kcLsAHHfmxa4LGzgS8M6ANHSQZ1NDhIWXRBQIONHDQAAcEHBBwIIGDjsCtCxo2CEDDBjVsgLBBCzZQsEELNsBXDRvUsIGEDTRs0CHUug-Y9-b1dLJv1cLxl7Lejf-vW2PwkG3hJcWPGIRzZ45TvpEdodk7cvY8Ox46_X5kRzSxs6PHrH_l4Z9c45in7LZm8xnbKldV_BxnD2X4Qty_vwA9vSlW |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+phase+2%2C+open-label%2C+single-arm+study+evaluating+the+combination+of+pembrolizumab+%28pembro%29%2C+lenvatinib%2C+and+chemotherapy+in+patients+%28pts%29+with+metastatic+non-small+cell+lung+cancer+%28NSCLC%29+harbouring+a+targetable+mutation+who+experienced+disease+progression+on+standard+tyrosine+kinase+inhibitors+%28TKIs%29&rft.jtitle=Journal+of+clinical+oncology&rft.au=Chan%2C+Hoi+Wai&rft.au=Tse%2C+Chris+Chun+Long&rft.au=Li%2C+Yu-Chung&rft.au=Leung%2C+Roland+Ching-Yu&rft.date=2024-08-10&rft.issn=0732-183X&rft.eissn=1527-7755&rft.volume=42&rft.issue=23_suppl&rft.spage=198&rft.epage=198&rft_id=info:doi/10.1200%2FJCO.2024.42.23_suppl.198&rft.externalDBID=n%2Fa&rft.externalDocID=10_1200_JCO_2024_42_23_suppl_198 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0732-183X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0732-183X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0732-183X&client=summon |